Feb 27 |
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
Feb 25 |
Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
|
Feb 21 |
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
|
Feb 15 |
Steven Cohen Adjusts Position in Protagonist Therapeutics Inc
|
Feb 7 |
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
|
Feb 2 |
Protagonist (PTGX) Up 14% on Licensing Deal With Takeda
|
Feb 1 |
Protagonist Therapeutics stock rises on Takeda license deal
|
Feb 1 |
Takeda pays $300M to license Protagonist drug for blood disorder
|
Jan 31 |
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
|
Jan 29 |
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024
|